BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
01 déc. 2021 07h00 HE
|
BioXcel Therapeutics
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN, Conn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:...
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
11 nov. 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
10 nov. 2021 07h00 HE
|
BioXcel Therapeutics
Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of...
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
27 oct. 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
18 oct. 2021 07h00 HE
|
BioXcel Therapeutics
Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell...
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day
23 sept. 2021 07h00 HE
|
BioXcel Therapeutics
Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders Company to introduce BXCL502 program and discuss expansion opportunities for lead program, BXCL501 ...
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
15 sept. 2021 18h06 HE
|
BioXcel Therapeutics
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety...
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
12 sept. 2021 18h05 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
09 sept. 2021 07h00 HE
|
BioXcel Therapeutics
Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
10 août 2021 07h00 HE
|
BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...